Insulin resistance marker for Alzheimer's prognosis
Part of Brain & nervous system, Mental health clinical trials.
This study looks at whether a marker of brain insulin resistance can help predict how mild cognitive impairment (MCI) progresses. It may help doctors better understand and plan care for people with MCI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been treated for mild cognitive impairment (MCI) at the Nancy CHRU CMRR for 1 to 2 years.
- You are covered by a social security scheme.
- You have not been diagnosed with Alzheimer's disease (AD).
- You are able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a simple blood test can help diagnose Alzheimer's disease and predict how the disease will progress. If you have memory or thinking problems that have been getting worse, you may be able to join.
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
This study looks at how giving insulin in a way that mimics the body's natural release can affect thinking and memory. It may help understand how insulin relates to brain health.
This study looks for “biomarkers” (measurable signs from blood and brain tests) that may help predict who with mild cognitive impairment (MCI) could later develop dementia. Results may help doctors spot risk earlier and better plan care.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.